Reporter Seongmin Kim, Bio Spectator
Signed a global license agreement for the development of two bio products…”Alteogen sells itself in the Asian market except for three countries…Alteogen supplies ALT-B4 clinical and commercial quantities”
Alteogen has signed an exclusive global license agreement with Intas Pharmaceuticals Ltd for the human hyaluronidase’ALT-B4′ using Hybrozyme™ technology 7 Sun said. It is a deal six months after Alteogen signed two technology transfer contracts with 10 major pharmaceutical companies.
According to the contract, Alteogen gave Intas the right to commercialize it early in the world except for three countries in the Asian market after developing two bio products for subcutaneous injection using ALT-B4.
Alteogen will receive a down payment of 6 million dollars (approximately 6.6 billion won) from Intas and a total of 190 million dollars (approximately 120 billion won) as milestones according to clinical development, sales permits, and sales performance of products. In addition, when commercializing a product, it receives a maximum of two digits of royalties depending on net sales.
The quantity of ALT-B4 for clinical development and commercial sale for mixing in bio-products is produced under the responsibility of Alteogen and supplied to Intas.
Park Soon-jae, CEO of Alteogen, said, “We are pleased to sign a contract with Intas, which is rapidly growing in the generic medicine field. “It is meaningful that in the future, Alteogen has laid the foundation for a leap forward as a global bio company by selling its contracted products in major Asian countries in the future.”
Binish Chudgar, Vice Chairman of Intas, said, “The original technology of Alteogen, the development power of Intas, and commercial capabilities such as manufacturing are combined.” And improve the quality of patient care.”
ALT-B4 is a technology that temporarily hydrolyzes hyaluronan from the extracellular matrix and converts intravenous injections of protein preparations into subcutaneous injections. Specifically, it is a PH20 variant that binds the Hyal domain to hyaluronidase PH20. It is a technology designed to improve enzyme activity and thermal stability (aggregation temperature) while maintaining the mechanism of action of PH20. It is explained that Alteogen has secured competitiveness in non-clinical conditions such as improving protein stability through increased thermal safety, high productivity, and improved immunogenicity compared to existing drugs in in vitro analysis.
Meanwhile, Intas is a pharmaceutical drug development, manufacturing and marketing company operating in more than 85 countries around the world. Over the past five years, it has grown by an average of about 26% annually, and last year’s sales exceeded $2 billion. It has a subsidiary Accord Healthcare for marketing and sales in markets in the EU, US, Canada, South Africa, Australia, Asia Pacific, CIS and MENA.